Insider Buying: Neos Therapeutics Inc (NEOS) Director Acquires 43,478 Shares of Stock

Neos Therapeutics Inc (NASDAQ:NEOS) Director Alan L. Heller purchased 43,478 shares of the stock in a transaction that occurred on Thursday, November 8th. The stock was acquired at an average cost of $2.30 per share, with a total value of $99,999.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

NEOS stock opened at $2.59 on Friday. Neos Therapeutics Inc has a twelve month low of $2.27 and a twelve month high of $11.69.

Neos Therapeutics (NASDAQ:NEOS) last posted its quarterly earnings data on Friday, November 9th. The company reported ($0.43) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.03). The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $14.80 million. Neos Therapeutics had a negative net margin of 164.40% and a negative return on equity of 586.25%. On average, analysts anticipate that Neos Therapeutics Inc will post -1.8 EPS for the current fiscal year.

A number of equities analysts recently issued reports on the company. Zacks Investment Research raised Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 11th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 price target on shares of Neos Therapeutics in a report on Wednesday, August 8th. Wells Fargo & Co lowered their price target on Neos Therapeutics from $14.00 to $11.00 and set a “buy” rating for the company in a report on Thursday, August 9th. Finally, ValuEngine raised Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, September 18th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Neos Therapeutics has an average rating of “Hold” and a consensus price target of $15.50.

Hedge funds have recently bought and sold shares of the company. Schwab Charles Investment Management Inc. boosted its holdings in shares of Neos Therapeutics by 28.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 56,200 shares of the company’s stock valued at $352,000 after acquiring an additional 12,500 shares during the period. Millennium Management LLC boosted its holdings in shares of Neos Therapeutics by 171.9% in the second quarter. Millennium Management LLC now owns 170,045 shares of the company’s stock valued at $1,063,000 after acquiring an additional 107,515 shares during the period. Proxima Capital Management LLC boosted its holdings in shares of Neos Therapeutics by 34.1% in the second quarter. Proxima Capital Management LLC now owns 295,000 shares of the company’s stock valued at $1,844,000 after acquiring an additional 75,000 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of Neos Therapeutics in the second quarter valued at approximately $469,000. Finally, Allianz Asset Management GmbH acquired a new stake in shares of Neos Therapeutics in the first quarter valued at approximately $161,000. 46.88% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Insider Buying: Neos Therapeutics Inc (NEOS) Director Acquires 43,478 Shares of Stock” was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.wkrb13.com/2018/11/11/insider-buying-neos-therapeutics-inc-neos-director-acquires-43478-shares-of-stock.html.

About Neos Therapeutics

Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.

Featured Story: Capital Gains

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply